Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Total Liabilities

Everything the company owes to creditors and other parties.

Pharvaris N.V.NASDAQ: PHVS

Total Liabilities · Q3 FY2026 · quarter ended Sep 2026

Total liabilities rises 12.9% from a year ago

Total liabilities stood at €30.09M at the end of Q3 FY2026, up 12.9% from a year earlier and up 8.0% from the prior quarter. Over 3 fiscal years it compounded at +17.8% a year.

Context

  • Total liabilities amounted to 10.2% of total assets at the end of Q3 FY2026, up 2.3 pp from a year earlier.
  • Total liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total liabilities keeps rising in the next quarterly balance sheet after a +12.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
€30.09M+8.0% QoQ
Last fiscal yearDec 2025
€30.18M+27.8% YoY
Year agoSep 2025
€26.66M+12.9% since
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.9%——
1 year+27.8%——
3-year CAGR+17.8%——
5-year CAGR——
10-year CAGR——

Total Liabilities history

EUR · from the balance sheet

Latest · FY2025
30.18M EUR
Year-over-year change
+27.8%
4-year CAGR
+43.4%

Total Liabilities vs competitors

How PHVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +12.9% is the 6th highest of 7, against a peer median of +16.2%.
  • Total liabilities amounts to 10.2% of total assets for PHVS, versus a peer median of 45.5%.
PHVS Competitors
Total Liabilities for PHVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$5.31T USD+340892.5%-5.3%45.9%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026$1.01B USD+15.2%-9.2%181.4%
TVTXTravere Therapeutics, Inc.Sep 2026$825.65M USD+77.6%-8.0%97.3%
PHARPharming Group N.V.Mar 2026$220.41M USD+17.3%+0.2%45.0%
VERAVera Therapeutics, Inc.Jun 2026$125.23M USD+13.6%+33.7%23.5%
PHVSPharvaris N.V.Sep 2026€30.09M EUR+12.9%+17.8%10.2%
RLYBRallybio CorporationMar 2026$4.2M USD+7.3%-27.1%7.7%
Peer median (excluding PHVS) —+16.2%-6.6%45.5%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents209.35M161.84M391.23M280.73M291.68M
Short-term Investments00000
Net Receivables700.08K382.47K1.04M2.94M4.55M
Inventory04.04M000
Other Current Assets5.7K582.59K620.82K00
Total Current Assets211.57M166.85M397.85M289.42M299.17M
Property, Plant & Equipment (Net)351.35K626.44K455.57K1.48M1.4M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets172.05K259.8K387.53K474.35K887.35K
Other Non-current Assets00000
Total Non-current Assets523.4K886.24K843.1K1.96M2.29M
Total Assets212.09M167.73M398.69M291.37M301.45M
Account Payables2.13M5.98M2.91M4.56M5.11M
Short-term Debt00000
Tax Payables491.22K1.17M430.28K601.25K941.21K
Deferred Revenue00000
Other Current Liabilities1.46M461.3K429.92K7.83M11.43M
Total Current Liabilities6.99M18.22M14.6M22.97M29.6M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities(1)0000
Total Non-current Liabilities150.75K249.42K43.56K639.04K576.59K
Total Liabilities7.14M18.47M14.65M23.61M30.18M
Common Stock3.98M4.06M6.27M6.53M7.83M
Retained Earnings(87.57M)(164.19M)(265.92M)(402.26M)(579.6M)
Accumulated OCI9.8M20.21M27.88M39.85M50.5M
Other Stockholders Equity00000
Minority Interest00000
Total Equity204.95M149.26M384.05M267.76M271.27M
Total Debt250.18K436.82K238.91K861.47K776.8K
Net Debt(209.1M)(161.4M)(390.99M)(279.87M)(290.9M)

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.